[TuPe1.1C23] Efficacy of peginterferon α-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in patients with HCV genotype 4 infection in the AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT)

3rd International AIDS Society Conference on HIV Pathogenesis and Treatment

Rio de Janeiro - July 24 - 27, 2005

EFFICACY OF PEGINTERFERON α-2a (40KD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) IN PATIENTS WITH HCV GENOTYPE 4 INFECTION IN THE AIDS PEGASYS RIBAVIRIN INTERNATIONAL CO-INFECTION TRIAL (APRICOT)

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuPe1.1C23

Soriano V.¹, Mendes-Correa M.C.², Gonçales Jr. F.L.³, Torriani F.J.⁴, Dieterich D.T.⁵, Cahn P.⁶, Findor J.A.⁷, Cassetti I.⁸, Sette Jr. H.⁹
¹Hospital Carlos III, Madrid, Spain, ²Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Casa da AIDS, São Paulo, Brazil, ³Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ⁴University of California, San Diego, United States of America, ⁵Mount Sinai School of Medicine, New York, United States of America, ⁶Fundacion Huesped, Buenos Aires, Argentina, ⁷Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina, ⁸Fundacion Centro de Estudios Infectologicos, Buenos Aires, Argentina, ⁹Instituto de Infectologia Emilio Ribas, São Paulo, Brazil

INTRODUCTION: Patients infected with HCV genotype 1 or 4 generally achieve similar SVR rates with antiviral therapy. In HIV-HCV co-infected patients treated with PEGASYS®/COPEGUS® in APRICOT (N Engl J Med. 2004 Jul 29;351(5):438-50) the SVR rate was 40% overall and 29% in those with genotype 1 infection. We examined the efficacy of treatment of patients infected with HCV genotype 4 enrolled in APRICOT.

METHODS: HCV-treatment-naïve patients with HIV-HCV co-infection were randomized to PEGASYS® 180µg/wk plus COPEGUS® 800mg/day (RBV), PEGASYS® plus placebo or conventional interferon 3MIU three times weekly plus RBV for 48wks. SVR was defined as serum HCV RNA <50 IU/mL at the end of untreated follow-up (wk72).

RESULTS: (ITT) In APRICOT, 60/860 patients (7%) had genotype 4 infection. Baseline characteristics and virological response rates are presented below. For patients treated with PEGASYS®/COPEGUS® the overall SVR rate was 38%: 27% in patients with high viral titers (>800,000 IU/mL) and 60% with low viral titers (≤800,000 IU/mL).

CONCLUSIONS: Although the number of patients in APRICOT with genotype 4 was small, a 38% SVR rate in genotype 4 patients reflects the overall virological response rates in APRICOT (40%) for patients treated with PEGASYS®/COPEGUS®. This 38% SVR rate in genotype 4 patients treated with PEGASYS®/COPEGUS® is higher than that achieved in patients treated with genotype 1 infection.

Download PDF of this abstract.

050724
Clinical | TuPe1.1C23 | Vincent Soriano
Hepatitis viruses

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.